NRG Fusion Market
Dec 16, 2024
Merus’ BIZENGRI: The New Face of NRG1+ Cancer Treatment After FDA Approval
Merus had a standout start this month. Shortly after landing a long-anticipated commercialization partner for its zenocutuzumab, the drug has achieved FDA approval, becoming the first therapy to target cancers with a neuregulin 1 (NRG1) gene fusion. The FDA granted accelerated approval to the drug, now marketed ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
